First Pharmaceutical Holdings announced that revenue for the third quarter of 2026 was 65.2347 million yuan, net profit of 165.17,500 yuan, after deducting non-net profit of 139.1331 million yuan; revenue for the first three quarters of 2026 was 93.2347 million yuan, up 4,561.73% year-on-year, with a net profit loss of 44.542 million yuan, net profit loss of 53.27 million yuan. According to the announcement, milestone revenue and cooperative revenue from cooperative R&D projects have increased, and commercial supply and sales of cantertinib granules have begun, driving revenue growth.

First Pharmaceutical Holdings announced that revenue for the third quarter of 2026 was 65.2347 million yuan, net profit of 165.17,500 yuan, after deducting non-net profit of 139.1331 million yuan; revenue for the first three quarters of 2026 was 93.2347 million yuan, up 4,561.73% year-on-year, with a net profit loss of 44.542 million yuan, net profit loss of 53.27 million yuan. According to the announcement, milestone revenue and cooperative revenue from cooperative R&D projects have increased, and commercial supply and sales of cantertinib granules have begun, driving revenue growth.